Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies
08 Abril 2024 - 6:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR), the leading provider of
nuclear magnetic resonance (NMR) systems, today announces novel
magnet technology and analytical solutions to support broad
adoption of NMR in academic basic and clinical research, as well as
in biopharma drug discovery, development and process analytical
technologies (PAT).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240408534756/en/
Ascend Evo 600 NMR magnet with a 1-year
liquid helium hold-time (Photo: Business Wire)
At the 65th ENC (www.enc-conference.org), Bruker introduces the
Ascend Evo 600, a novel compact 54 mm standard-bore 14.1
Tesla (600 MHz) NMR magnet, which features a full one-year liquid
Helium hold-time, more than doubling refill intervals. The Ascend
EvoTM 600 is the latest addition to the Evo magnet series, which
includes compact 1 GHz, 900 MHz, 500 MHz, and 400 MHz magnets
operating at 4.2 K, employing advanced superconducting magnet coil
and cryogenic technology. The new Ascend Evo 600 magnet is easier
to site, has reduced installation and operational costs, and has
lower Helium consumption compared to previous 600 MHz magnets.
Importantly, it features an unprecedented, more than doubled
one-year Helium hold-time for easier lab deployment, less
maintenance, and further improved sustainability. With the Ascend
Evo series, Bruker makes NMR more accessible to researchers across
various fields, from clinical metabolism research to the biopharma
industry, enabling advanced characterization of biologics and new
drug modalities.
In addition, Bruker expands the applications of its Fourier 80
platform, a benchtop 80 MHz Fourier Transform NMR with a
high-performance permanent magnet that requires no cryogens or
power. The Fourier 80 can now be integrated with synTQTM PAT
management software for synchronization with sensors and other
analytical techniques, such as IR or Raman spectroscopy, for
multiple, integrated data streams that provide more comprehensive
process analysis and quality control. The Fourier PAT solution
reduces tedious calibrations and enhances (bio)process control by
providing a wealth of structural information, selectivity, and
direct quantification in lab or manufacturing settings.
The Fourier PAT solution can be deployed in distributed
manufacturing of Active Pharmaceutical Ingredients (APIs). Here,
the Fourier 80 system gathers reaction data for AI machine learning
to formulate the rules and actions to guide process
optimization.
Mr. Philippe Robin, Founder and CEO of Alysophil, commented:
“This PAT setup is game-changing in the way we produce APIs,
enabling distributed manufacturing and on-demand production.
Coupling the PAT module with our AI agent in our API manufacturing
unit enhances the advantages that accompany flow chemistry, such as
increased safety, reduced environmental footprint and better
economics.”
About Bruker Corporation – Leader of the Post-Genomic Era
(Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough
post-genomic discoveries and develop new applications that improve
the quality of human life. Bruker’s high performance scientific
instruments and high value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular, and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity,
and customer success in post-genomic life science molecular and
cell biology research, in applied and biopharma applications, in
microscopy and nanoanalysis, as well as in industrial and cleantech
research, and next-gen semiconductor metrology in support of AI.
Bruker offers differentiated, high-value life science and
diagnostics systems and solutions in preclinical imaging, clinical
phenomics research, proteomics and multiomics, spatial and
single-cell biology, functional structural and condensate biology,
as well as in clinical microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240408534756/en/
Investor Contact: Justin Ward Sr. Director, Investor
Relations & Corporate Development Bruker Corporation T: +1
(978) 313-5800 E: Investor.Relations@bruker.com
Media Contact: Markus Ziegler Sr. Director and Head of
Group Marketing Bruker BioSpin T: +49 172 3733531 E:
pr@bruker.com
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024